VYNE
NASDAQVYNE Therapeutics Inc.
News · 26 weeks55-77%
2026-03-012026-08-23
Mix4590d
- Insider24(53%)
- SEC Filings14(31%)
- Other4(9%)
- Dividends3(7%)
Latest news
25 items- SECSEC Form EFFECT filed by VYNE Therapeutics Inc.EFFECT - Yarrow Bioscience, Inc. (0001566044) (Filer)
- SECSEC Form POS AM filed by VYNE Therapeutics Inc.POS AM - Yarrow Bioscience, Inc. (0001566044) (Filer)
- SECAmendment: VYNE Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Regulation FD Disclosure8-K/A - Yarrow Bioscience, Inc. (0001566044) (Filer)
- SECSEC Form 10-Q filed by VYNE Therapeutics Inc.10-Q - Yarrow Bioscience, Inc. (0001566044) (Filer)
- SECSEC Form SCHEDULE 13G filed by VYNE Therapeutics Inc.SCHEDULE 13G - Yarrow Bioscience, Inc. (0001566044) (Subject)
- SECSEC Form SCHEDULE 13D filed by VYNE Therapeutics Inc.SCHEDULE 13D - Yarrow Bioscience, Inc. (0001566044) (Subject)
- SECSEC Form SCHEDULE 13G filed by VYNE Therapeutics Inc.SCHEDULE 13G - Yarrow Bioscience, Inc. (0001566044) (Subject)
- INSIDERLarge owner Rtw Fund Group Gp, Llc disposed of 133,290 shares (SEC Form 4)4 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- SECSEC Form 8-K filed by VYNE Therapeutics Inc.8-K - Yarrow Bioscience, Inc. (0001566044) (Filer)
- INSIDERNew insider Rtw Fund Group Gp, Llc claimed ownership of 399,597 shares (SEC Form 3)3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERSEC Form 4 filed by Director Ashiya Mona4 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERSEC Form 4 filed by Director Zeronda Tyler4 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERNew insider Orbimed Advisors Llc claimed ownership of 266,306 shares (SEC Form 3)3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERNew insider Ashiya Mona claimed ownership of 266,306 shares (SEC Form 3)3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERSEC Form 3 filed by new insider White William Richard3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERSEC Form 3 filed by new insider Silverman Peter B.3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lundberg Sven Ante3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hoerter Steven L.3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERSEC Form 3 filed by new insider Alford Rachael3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERSEC Form 3 filed by new insider Payton Lori3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ryder Steven3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERSEC Form 3 filed by new insider Frey Rebecca3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERNew insider Perceptive Advisors Llc claimed ownership of 266,309 shares (SEC Form 3)3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- SECVYNE Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Yarrow Bioscience, Inc. (0001566044) (Filer)
- INSIDERCHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 22,516 shares, decreasing direct ownership by 23% to 74,918 units (SEC Form 4) (withholding obligation)4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
VYNE FAQ
7 questionsWhat does VYNE Therapeutics Inc. do?
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib...Where does VYNE stock trade?
VYNE Therapeutics Inc. (VYNE) is listed on NASDAQ.What sector and industry is VYNE in?
VYNE Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did VYNE Therapeutics Inc. go public?
VYNE Therapeutics Inc. (VYNE) completed its IPO in 2018.What are analysts saying about VYNE?
VYNE Therapeutics Inc. has had 3 recent analyst actions on file. The most recent action was from BTIG Research: Neutral on 2025-07-31. Recent price targets range from $700.00 to $800.00.What companies are similar to VYNE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare VYNE side-by-side with any of them on Quantisnow.How can I track VYNE on Quantisnow?
Quantisnow aggregates VYNE Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VYNE to receive live email and push alerts on every new disclosure.